|Chennai||Rs. 25020.00 (0.81%)|
|Mumbai||Rs. 25890.00 (0.98%)|
|Delhi||Rs. 25200.00 (-0.2%)|
|Kolkata||Rs. 25480.00 (1.03%)|
|Kerala||Rs. 24800.00 (0.61%)|
|Bangalore||Rs. 25000.00 (0.81%)|
|Hyderabad||Rs. 25080.00 (1.09%)|
Reuters Market Eye - Shares in Sun Pharmaceutical Industries
Currently the drug, Ibandronate Sodium, is marketed by Roche under the brand name Bovina.
"Bovina generated an annual sales of $82 million in 2012. Currently, Sun Pharma is the only generic player to have final approval for this product," brokerage Sharekhan said in a note on Wednesday.
More players would be able to sell the drug after its patent expiry on September 2, 2014, Sharekhan said.
(Reporting by Abhishek Vishnoi)